The LLM Inflection Point Moment and the Implications for the Specialty Pharmaceutical Industry
Failed to add items
Add to basket failed.
Add to Wish List failed.
Remove from Wish List failed.
Follow podcast failed
Unfollow podcast failed
The LLM Inflection Point Moment and the Implications for the Specialty Pharmaceutical Industry
-
Narrated by:
-
By:
About this listen
Recent advancements in AI and Large Language Models (LLMs) have caught the world’s attention and for good reason. It’s a big deal.
Specialty pharmaceuticals are typically costly, sometimes ranging from $10,000 to over $5 million per patient, per year. The onboarding and approval process that come with these drugs are complex, requiring extensive effort from manufacturers and patients to get enrolled. Despite massive investments in people, processes, and systems, engagement remains a struggle for all.
In this episode of Digital Conversations, Greg Johnsen and Greg Kefer discuss the implications of bringing conversational technology to the specialty pharma industry and how digital assistants use smart, compliant language to interact with patients and guide them along their journeys from prescription moment to program enrollment to first fill, and beyond.